Currently, immune checkpoint inhibitors targeting either PD-1 or PD-L1 have become part of the standard treatment for late-stage, PD-L1-expressing NSCLC with no molecular drivers. The gene discussed is CD274; the disease is non-small cell lung carcinoma.